TY - JOUR
T1 - New and emerging therapies in psoriasis.
AU - Leonardi, Craig L.
AU - Gordon, Kenneth B.
PY - 2014/3
Y1 - 2014/3
N2 - This article discusses the scientific rationale for the use of cytokine inhibitors, including ustekinumab, an inhibitor of the interleukin (IL)-12 and IL-23 pathways in psoriasis. Also addressed are the efficacy and safety data for this agent, as well as for several emerging therapies that target other cytokine pathways in psoriasis: the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab, the IL-23 blocker tildrakizumab, and the small-molecule kinase inhibitors apremilast (a phosphodiesterase-4 blocker) and tofacitinib (a Janus kinase inhibitor). 2014 published by Frontline Medical Communications.
AB - This article discusses the scientific rationale for the use of cytokine inhibitors, including ustekinumab, an inhibitor of the interleukin (IL)-12 and IL-23 pathways in psoriasis. Also addressed are the efficacy and safety data for this agent, as well as for several emerging therapies that target other cytokine pathways in psoriasis: the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab, the IL-23 blocker tildrakizumab, and the small-molecule kinase inhibitors apremilast (a phosphodiesterase-4 blocker) and tofacitinib (a Janus kinase inhibitor). 2014 published by Frontline Medical Communications.
UR - http://www.scopus.com/inward/record.url?scp=84905588626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905588626&partnerID=8YFLogxK
U2 - 10.12788/j.sder.0071
DO - 10.12788/j.sder.0071
M3 - Article
C2 - 24979544
AN - SCOPUS:84905588626
SN - 1085-5629
VL - 33
SP - S37-41
JO - Seminars in cutaneous medicine and surgery
JF - Seminars in cutaneous medicine and surgery
IS - 2 Suppl 2
ER -